The rise of NP/PA influence is not a passing trend; it is a structural realignment of US healthcare. These clinicians are the connective tissue.
The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional.
The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
Editor's Picks
